分类： health

Delhi, the Indian capital, is grappling with a severe air pollution crisis, with children emerging as the most vulnerable victims. Hospitals across the city are witnessing a surge in young patients suffering from respiratory issues, a direct consequence of the hazardous air quality. The situation has reached alarming levels, with the Air Quality Index (AQI) consistently hovering between 300 and 400, far exceeding the World Health Organization’s recommended limit. Fine particulate matter (PM2.5), which can penetrate deep into the lungs, is a major contributor to the health crisis. Pediatric clinics are overwhelmed, with doctors reporting a tenfold increase in pollution-related illnesses among children. Dr. Shishir Bhatnagar, a pediatrician in Noida, noted that 50-70% of his patients during the pollution season suffer from breathing difficulties, compared to 20-30% in normal times. The government has implemented emergency measures, including halting construction and banning polluting vehicles, but these efforts have failed to curb the smog. Parents like Khushboo Bharti, whose one-year-old daughter Samaira was hospitalized with pneumonia, are living in constant fear. Research underscores the long-term health risks for children, including stunted development, weakened immunity, and cognitive impairments. A recent study from the University of Cambridge linked air pollution to a higher risk of dementia. Many families are considering relocating to safer environments, but for the economically disadvantaged, escape is not an option. Dr. A Fathahudeen, a pulmonologist, warns that chronic exposure to pollution can lead to irreversible lung damage in children. While schools have shifted to hybrid learning and outdoor activities have been curtailed, parents question how long they can keep their children indoors. The crisis has sparked protests and calls for urgent action to protect the health of Delhi’s youngest residents.

A landmark regulatory shift by the U.S. Food and Drug Administration (FDA) to eliminate stringent ‘black box’ warnings from most menopausal hormone replacement therapy (HRT) products is being celebrated as a transformative development for women’s healthcare in the United Arab Emirates. Medical professionals predict this decision will catalyze a significant surge in women seeking treatment, empowering them to pursue personalized strategies for managing menopause symptoms.

The FDA’s action reverses a decades-old cautionary stance established in the early 2000s, which was based on a study that initially suggested a non-significant increase in breast cancer risk. This warning had created widespread apprehension, causing a dramatic decline in HRT usage. The updated regulatory position now aligns with contemporary scientific evidence demonstrating that initiating therapy within ten years of menopause onset, or before age 60, presents a favourable risk-benefit profile for most women.

Dr. Aysha Salam, Specialist in Obstetrics and Laparoscopic Gynaecology at Aster Hospital Mankhool, described the development as “a pivotal moment for women in the UAE, potentially leading to increased access to evidence-based menopausal care.” She emphasized that this change facilitates more informed health decisions, moving away from a generalized approach to menopause management.

The emotional resonance of this decision is profound among UAE residents. Dubai resident Fathimath Shehnaz characterized HRT as a “lifesaver” that alleviated her severe symptoms following a hysterectomy. “The hot flashes were unbearable,” she recounted. “Within one day of starting treatment, I could feel the difference.”

Despite established benefits—including a documented 50% reduction in heart attack risk, 64% decrease in cognitive decline, and 35% lower Alzheimer’s risk—persistent misconceptions continue to deter women from treatment. Dr. Milena Caccelli, Endocrinologist at metabolic.health, noted that outdated fears surrounding cancer and cardiovascular risks have created disproportionate anxiety, often causing women to delay seeking appropriate medical care.

Medical experts conclude that the FDA’s updated stance will foster more individualized prescribing practices, enhance patient-clinician dialogue, and ultimately improve quality of life for women navigating menopause by providing clearer access to safe and effective treatments.

Turkey has emerged as a premier destination for hair transplantation, offering a unique blend of affordability, quality, and comprehensive care. With costs ranging from $2,500 to $6,500, Turkish clinics provide a cost-effective alternative to Western countries like the UK, Europe, and the US. Renowned clinics such as Asli Tarcan Clinic employ experienced surgeons and utilize advanced techniques, ensuring natural results and a seamless recovery process.

What sets Turkey apart is its all-inclusive packages, which typically cover accommodation, airport transfers, surgery, and aftercare. Patients can enjoy stays in 4- or 5-star hotels, private airport transfers, and access to specialized medical expertise. The competitive pricing is driven by factors such as affordable living costs, a robust medical tourism industry, and shorter waiting times.

Turkish clinics also prioritize aftercare, offering virtual consultations, wound care instructions, medication guidance, and more. The success rate of hair transplants in Turkey exceeds 95%, making it a reliable choice for international patients. Additionally, the country’s convenient tourism arrangements, from arrival to departure, enhance the overall experience.

Choosing the right clinic and understanding the inclusions in the package are crucial for a successful treatment. With proper research and planning, patients can achieve long-lasting results and enjoy a comfortable, cost-effective medical tourism experience in Turkey.

Millions of diabetes patients worldwide may soon bid farewell to the discomfort of daily insulin injections, thanks to a groundbreaking discovery by Chinese researchers. A team led by scholars from Zhejiang University has achieved the world’s first non-invasive delivery of insulin through the skin, offering a pain-free alternative with efficacy comparable to traditional injections. The findings, published in the prestigious journal Nature, mark a significant leap in diabetes treatment. The innovative approach utilizes a polymer called OP, which exhibits exceptional permeability in skin tissues, enabling the delivery of insulin without disrupting the skin barrier. This breakthrough not only addresses the physical and psychological challenges associated with injections but also opens doors for the transdermal delivery of other biological macromolecules, such as therapeutic proteins and monoclonal antibodies. The technology, already transferred to enterprises for clinical translation, holds immense potential to revolutionize treatment for chronic diseases requiring long-term injections.

Traditional Chinese Medicine (TCM) is experiencing a significant surge in recognition and adoption across Australia and the Southern Hemisphere, driven by its holistic approach and growing integration with Western medical practices. Steven Wolfgang Sass, a Melbourne-based TCM practitioner, exemplifies this trend. His clinic, which opened nearly two years ago, has seen a steady increase in patients seeking relief from conditions ranging from chronic pain to stress-related ailments. Sass’s success stories, such as treating a neurologist with acupuncture, highlight TCM’s efficacy and its ability to complement conventional treatments.

In a significant stride towards combating thalassemia, the Southeast Asia Thalassemia Prevention Alliance (SEATPA) was officially launched in Chiang Mai, Thailand, on Monday. This groundbreaking initiative, spearheaded by BGI Group, a leading Chinese life sciences and genomics company, aims to eradicate preventable cases of this inherited blood disorder across Southeast Asia. Thalassemia, characterized by impaired hemoglobin synthesis and accelerated red blood cell destruction, poses a major public health challenge in the region due to its high prevalence. SEATPA’s mission is to foster cross-border collaboration, uniting countries, experts, and communities to enhance prevention and control efforts. The alliance will focus on capacity building, standardized training, technical unification, public awareness campaigns, and the sharing of expertise. Thailand’s Minister of Public Health, Pattana Promphat, emphasized the importance of regional cooperation in adapting modern medical technologies to local contexts and building a robust response to the disease. Wang Jian, co-founder and chairman of BGI Group, highlighted the necessity of global cooperation in precision medicine, stating that the alliance will bring advanced screening and treatment solutions to Southeast Asia, shifting the medical paradigm from passive treatment to active prevention. Piriya Cherdsatirakul, Vice-president of Chiang Mai University, lauded the alliance as a ‘significant milestone’ in improving the quality of life for thalassemia patients and offering new hope to the region.

Southwest China’s Guizhou province, home to 48 of the country’s 56 ethnic groups, has long been a hub of cultural and medicinal diversity. In Tongren, a city in Guizhou, Bai Yutao, a rehabilitation physician and acupuncturist, employs traditional Qiang ethnic techniques to treat patients. His method, known as ‘white-stone therapy,’ involves immersing polished stones in herbal broth, wrapping them in cloth, and rolling them across a patient’s back to release muscle tension. This fusion of ancient practices and modern medical care exemplifies Guizhou’s unique approach to traditional Chinese medicine (TCM).

Guizhou’s rich ethnic heritage has become a cornerstone of its TCM industry. At Jiangkou County Hospital of Traditional Chinese Medicine, Bai and his team have adapted Qiang manual techniques to meet clinical standards, ensuring safety and efficacy. Historically, ethnic healing systems like Miao and Qiang medicine included shamanistic elements and were passed down orally. However, as younger generations pursue formal education and urban jobs, the number of traditional healers is dwindling. Bai emphasizes the need to preserve these cultural roots while making them accessible to a broader audience.

In 2024, Tongren was designated a national pilot zone for the inheritance and innovative development of TCM. Efforts include standardizing treatments, regulating medicinal materials, and establishing quality control centers. The region is also leveraging its unique plant resources for economic growth. For instance, barrenwort, a herb known for strengthening tendons and bones, is cultivated in Jiangkou county and has become a staple in medicines and supplements. State-owned China National Pharmaceutical Group has partnered with local cooperatives to build the country’s largest barrenwort breeding base, providing technical guidance and purchase guarantees to farmers.

Guizhou’s aromatic and medicinal raw materials are also gaining international recognition. Companies like Guizhou Miaoyao Biotech Co export essential oils and plant extracts, with valerian oil being a major product. The company supports over 3,000 cooperative households and plans to expand its branded wellness products. This blend of tradition and innovation is transforming Guizhou’s healthcare landscape while boosting its economy.

In a groundbreaking study conducted at Delhi’s Maulana Azad Medical College, researchers have discovered that playing music to patients during surgery under general anaesthesia can significantly reduce the need for anaesthetic drugs and improve recovery outcomes. The study, published in the journal *Music and Medicine*, focused on patients undergoing laparoscopic cholecystectomy, a common keyhole procedure to remove the gallbladder.

China’s seven provincial-level cord blood banks have unveiled a comprehensive action plan to enhance research and clinical applications of cord blood. The initiative was announced at the 12th Cord Blood Symposium, organized by the Chinese Maternal and Child Health Association in Beijing. The participating banks, officially approved by the National Health Commission, are located in Beijing, Shanghai, Tianjin, and the provinces of Guangdong, Shandong, Sichuan, and Zhejiang.

The action plan focuses on increasing public awareness about cord blood and cell therapy, improving the quality of cord blood collection, and ensuring high standards in processing and cryopreservation. It also aims to promote the use of cord blood in clinical settings and advance research and applications at medical and scientific institutions.

Cord blood, collected from a newborn’s umbilical cord shortly after birth, has significant potential in treating various diseases. Wei Xiaofei, an official from the Beijing cord blood bank, highlighted that China has over 30 years of experience in cord blood storage and application. The seven official banks have collectively stored more than 2.45 million units of cord blood and released over 45,000 units for clinical use.

‘The action plan enables the seven cord blood banks to leverage their respective strengths, collaborate on targeted research, develop high-quality solutions, and jointly accelerate the translation of scientific achievements into clinical practice,’ Wei stated.

Sun Zimin, a professor from the Institute of Hematology & Blood Diseases Hospital at the Chinese Academy of Medical Sciences, noted that cord blood can now be used to treat nearly 80 diseases, including leukemia, aplastic anemia, immunodeficiency disorders, genetic metabolic diseases, and certain neurological conditions. She added that through optimizing pretreatment and supportive care, the stable engraftment rate of cord blood transplantation in clinical practice has risen to over 97 percent.

Sun emphasized the importance of establishing larger and higher-quality public cord blood banks to provide lifesaving opportunities for more patients, especially those in urgent need of a transplant who are unable to find a suitable match.